“NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW”
Waregem (Belgium) / Rotterdam (The Netherlands)[1], 8 April 2014 – Arseus NV has been informed that Waterland Private Equity Fund IV C.V., through its subsidiaries Enhold NV and Supply Holding B.V. (“Waterland”), intends to sell, through a private placement, up to approximately 6.27 million shares held by it in Arseus, representing up to 20% of Arseus’ currently outstanding capital. The private placement will be conducted by means of an accelerated bookbuilding.
Until the results of the private placement are announced, trading of the Arseus shares on NYSE Euronext Brussels and NYSE Euronext Amsterdam will be temporarily suspended.
Waterland has agreed to a lock-up of 180 calendar days for all Arseus shares not sold in the private placement, subject to customary carve-outs.
The results of the private placement will be announced shortly after completion of the bookbuilding process and settlement is expected to occur on the third business day after announcement of the private placement results.
Important notice
The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. We understand that any securities offered in the private placement have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States without registration thereunder or pursuant to an available exemption there from. Neither this document nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy securities in the United States.
For further information:
Marieke Palstra
Director Investor Relations
+ 31 88 33 11 213
marieke.palstra@arseus.com
Arseus profile
Arseus is a scientific R&D company that supplies innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries around the world. Arseus is made up of three divisions: Fagron is the global market leader in pharmaceutical compounding. Corilus develops and supplies medical specialists with unique integrated ICT solutions with substantial added value. Corilus is the market leader in selected segments in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.